In vitro and in vivo anticancer activities of a novel antibiotic
IC50 for nine cancer cell lines was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays. In KM mice bearing sarcoma S180 that was treated with subcutaneous (s.c.) injection of antibiotic BS, marked cures were obtained. In terms of tumor weight, the treated/control = 0.43. The conclusion is that BS merit further investigation as a potential anti-cancer candidate drug.
Key word: Antibiotic, Bacillus subtilis, in vivo, in vitro, antitumor.